<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230703058652N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-09-13</date_registration>
      <primary_sponsor>Ahvaz University of Medical Sciences</primary_sponsor>
      <public_title>intraarticular vancomycin in hip hemiarthroplasty</public_title>
      <acronym></acronym>
      <scientific_title>The effects of intraarticular vancomycin in preventing infection in patients undergoing hip hemiarthroplasty</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-06-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>48</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71079</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: from 48 patients that will meet the conditions for entering the study, they will be randomized using the block randomization method and blocks size of four and will be divided into two groups receiving vancomycin and the group not receiving vancomycin in surgery wound.
According to the number of study patients, which is 48, the number of 12 blocks with size of 4 is determined for each block. After determining the number of blocks and the capacity of each block, randomization of patients within the block is done using pre-written cards.
We consider group A as the group receiving vancomycin in the surgery wound, and group B as the group that does not receive vancomycin powder in the surgery wound.
2 cards named A and 2 cards named B are prepared , and we write the numbers 1 to 4 on the back of the cards, the number 1 is on the back of the A card, the number 2 is on the back of the B card, the number 3 is on the next A card, and the number 4 is on the next B card.
Then, by using the engineering calculator and choosing the RAND option and choosing the interval 1-4, we get random numbers from 1-4 and according to the number obtained from the calculator, we take the card and look at the back of it to see that A or It is B and the first card is placed in the first house of the first block, the second card is placed in the second house of the first block, the third card is placed in the third house of the first block, and the fourth card is placed in the fourth house of the first block.
We do this for all 12 blocks.
And during the surgery of the patients, we start from the first house of the first block. If it is group A, vancomycin powder will be poured into the wound, and if it is group B, vancomycin powder will not be poured into the wound. And for the next patients, we will select their groups from the first to the twelfth block respectively.</study_design>
      <phase>3</phase>
      <hc_freetext>Femoral neck fracture.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: a group of patients who, after surgery, one gram of vancomycin powder will be poured into their surgical wound, and after that, the subcutaneous fascia and skin will be repaired. Intervention 2: Control group: a group of patients who will not receive vancomycin powder in the surgical site after surgery, but all surgical procedures are similar except for receiving vancomycin powder.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The data file will be shared in the format of spss software. It should be noted that only the information related to the main consequences will be possible to share.

When:
Data access will start 6 months after publication

To whom:
The data will be available to researchers working in academic institutions.

Conditions:
Data will only be available for use in review studies and meta-analyses.

Where to obtain:
Payam mohammadhosseini by academic email
mohammadhoseini-p@ajums.ac.ir

How to obtain:
First, send an email to the author and mention the purpose of receiving the information. If there is no problem, you will receive the information one to three weeks later.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohsen asgari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Azadegan Street, Imam Khomeini Hospital, Ahvaz, Iran.</address>
        <city>Ahwaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6136683813</zip>
        <telephone>009884338301</telephone>
        <email>mohsenasgari8@gmail.com</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Payam mohammadhosseini</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Azadegan Street, Imam Khomeini Hospital, Ahvaz, Iran.</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6155693118</zip>
        <telephone>+98 61 3292 1836</telephone>
        <email>mohammadhoseini-p@ajums.ac.ir</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Femoral neck fracture patients candidates for primary hip hemiarthroplasty
Age over 50 years
Patient consent to participate in the study</inclusion_criteria>
      <agemin>50 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>patients that are candidate for total hip arthroplasty
known allergy to vancomycin
patients with renal disease and those have high creatinin level
active infection, local or systemic
patients with skin disorders in surgery site
patients undergo revision surgery
Auditory disorders
immunocompromization</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>S72.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Fracture of head and neck of femur</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: a group of patients who, after surgery, one gram of vancomycin powder will be poured into their surgical wound, and after that, the subcutaneous fascia and skin will be repaired.</i_keyword>
      <i_keyword>Control group: a group of patients who will not receive vancomycin powder in the surgical site after surgery, but all surgical procedures are similar except for receiving vancomycin powder.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Deep infection of surgery site. Timepoint: 7 , 14 , 30 , 60 , 90 days after surgery. Method of measurement: Inspection and physical examination.</prim_outcome>
      <prim_outcome>Superficial infection of surgery site. Timepoint: 7 , 14 , 30 , 60 , 90 days after surgery. Method of measurement: Inspection and physical examination.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Erythrocytecsedimentation rate. Timepoint: Before surgery and one month after surgery. Method of measurement: By blood test.</sec_outcome>
      <sec_outcome>C- reactive protein. Timepoint: Before surgery and one month after surgery. Method of measurement: By blood test.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ahvaz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-06-17</approval_date>
        <contact_name>Ethics committee of Ahwaz jondishapour University of Medical Sciences</contact_name>
        <contact_address>Jundishapur University of Medical Sciences, Esfand Ave, Golestan Blvd., Ahvaz, Iran. Ahvaz Khouzestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
